Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Oculis
With
ORA, Inc.
This is a Phase 2b, multicenter, randomized, double-masked, vehicle-control study designed to evaluate the efficacy and safety of licaminlimab for the treatment of signs and symptoms of dry eye disease.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Be at least 18 years of age.
Provide written informed consent.
Be willing and able to comply with all study procedures.
Have a history of dry eye disease for at least 6 months prior to Visit 1.
You may not be if
Have any clinically significant slit-lamp findings at least one eye at Visit 1 that may include active blepharitis, meibomian gland dysfunction, lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the Investigator may interfere with study parameters.
Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation in at least one eye at Visit 1 or Visit 2.
Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses in the study eye during the study.
Clareo Health | Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
